Financials data is unavailable for this security.
View more
Year on year Aurisco Pharmaceutical Co Ltd grew revenues 25.24% from 1.01bn to 1.26bn while net income improved 37.23% from 210.90m to 289.42m.
| Gross margin | 58.12% |
|---|---|
| Net profit margin | 26.44% |
| Operating margin | 29.87% |
| Return on assets | 15.19% |
|---|---|
| Return on equity | 20.07% |
| Return on investment | 19.04% |
More ▼
Cash flow in CNYView more
In 2023, Aurisco Pharmaceutical Co Ltd increased its cash reserves by 22.29%, or 75.47m. The company earned 385.61m from its operations for a Cash Flow Margin of 30.54%. In addition the company generated 49.02m cash from financing while 365.27m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.12 |
|---|---|
| Tangible book value per share | 4.82 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.22 |
|---|---|
| Quick ratio | 1.33 |
| Total debt/total equity | 0.1692 |
|---|---|
| Total debt/total capital | 0.1447 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 35.00%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.44% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 23.39% |
| EPS growth(5 years) | 13.31 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 97.93 |
More ▼
